J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00255-5. doi: 10.1016/j.jtho.2015.12.102. [Epub ahead of print]

• Response to crizotinib observed in lung adenocarcinoma with MET copy number gain but without high-level MET/CEP7 ratio, MET overexpression or exon 14 splicing mutations.
  Zhang Yan, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 12 (From HuGE Literature Finder)

Response to crizotinib observed in lung adenocarcinoma with MET copy number gain but without high-level MET/CEP7 ratio, MET overexpression or exon 14 splicing mutations.

Zhang Y1, Wang W2, Wang Y1, Xu Y1, Tian Y3, Huang M4, Lu Y1.

Author information

Abstract

Mesenchymal-epithelial transition (MET) is an important driver gene in non-small cell lung cancer (NSCLC). Yet, MET-relevant biomarkers to predictive clinical response of MET inhibitors remain elusive. Limited studies indicated some possibly effective biomarkers including amplification with high-level MET/CEP7 ratio, MET exon 14 (METex14) splicing mutations and overexpression. MET copy number gain (MCNG) is an independent negative prognostic factor in NSCLC. Therefore, whether or not MCNG as a predictive biomarker to MET inhibitors remains lack of clinical evidence. Here we report a lung adenocarcinoma patient with MCNG but without high-level MET/CEP7 ratio or METex14 splicing mutations who achieved a rapid response to crizotinib, indicating MCNG may be an independent predictive biomarker to MET inhibitors.

Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

MET/CEP7 ratio; Mesenchymal-epithelial transition; copy number gain; crizotinib; lung cancer

PMID:

 

26724472

 

[PubMed - as supplied by publisher]